Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.54 |
| ▸ | ERN1 | O75460 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20924569 | 0.88 | TSHR (0.56) | PTGS2SMN1; SMN2PTGS1ALDH1A1MAPT | |
| SCHEMBL6724685 | 0.86 | PTGS2 (0.75) | PTGS2PTGS1 | |
| SCHEMBL5715568 | 0.86 | PTGS2 (0.69) | PTGS2SMN1; SMN2ERN1HPGDLMNA | |
| SCHEMBL7412893 | 0.85 | SMN1; SMN2 (0.67) | PTGS2SMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL6728864 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL8974923 | 0.84 | PTGS2 (0.60) | PTGS2SMN1; SMN2PTGS1KDM4EALDH1A1 | |
| SCHEMBL8654693 | 0.84 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL8055958 | 0.81 | PTGS2 (0.78) | PTGS2PTGS1 | |
| SCHEMBL8044562 | 0.81 | PTGS2 (0.76) | PTGS2SMN1; SMN2PTGS1ERN1 | |
| SCHEMBL12326161 | 0.81 | PDGFRB (0.58) | PTGS2PTGS1KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149570-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149570-A1 | Piperidine derivative and use thereof | TACR1, OPRL1, TRPV1 | PTGS2 428/4885SMN1; SMN2 1617/4885PTGS1 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.